secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020075
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics Q1 net loss $63.9M on impairment charges; new CEO/CFO
------------------------------------------------------------------------

- Net loss of $63.9M in Q1 2023 vs $24.6M in Q1 2022; includes $32.9M IPR&D impairment and $13.1M long-lived asset impairment.
- Cash and equivalents $41.7M as of Mar 31, 2023; expects to fund operations into 2025.
- Clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 in ulcerative colitis; topline data expected in 2025.
- Executive leadership transition: Matthew Blischak to become CEO, Lance Thibault to become CFO effective May 16, 2023.
- Safety analysis from discontinued PRISM4 trial showed no drug-related serious adverse events among 19 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/0000950170-23-020075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/fnch-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer